Evidence map›Paper›PMID 39738001›Full record

ArticleNature communications2024

Systematic surveillance of SARS-CoV-2 reveals dynamics of variant mutagenesis and transmission in a large urban population.

Marie-Ming Aynaud, Lauren Caldwell, Khalid N Al-Zahrani, Seda Barutcu, Kin Chan, Andreea Obersterescu, Abiodun A Ogunjimi, Min Jin, Kathleen-Rose Zakoor, Shyam Patel and 19 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Marie-Ming Aynaud *Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5, Canada.ORCID 0000-0003-1788-3180
Lauren Caldwell *Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5, Canada.ORCID 0000-0001-9991-0757
Khalid N Al-Zahrani *Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5, Canada.ORCID 0000-0001-5771-7537
Seda BarutcuLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5, Canada.
Kin ChanLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5, Canada.
Andreea ObersterescuLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5, Canada.ORCID 0000-0003-3285-0221
Abiodun A OgunjimiLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5, Canada.
Min JinDepartments of Molecular Genetics and Biochemistry, University of Toronto, MaRS Center, Toronto, Ontario, M5G 1M1, Canada.ORCID 0009-0009-1155-9890
Kathleen-Rose ZakoorLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5, Canada.ORCID 0000-0002-6874-5223
Shyam PatelLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5, Canada.
Ron PadillaLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5, Canada.
Mark C C JenLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5, Canada.
Princess Mae VeniegasDepartment of Microbiology, Mount Sinai Hospital/University Health Network, Toronto, Ontario, M5G 1X5, Canada.
Nursrin DewsiDepartment of Microbiology, Mount Sinai Hospital/University Health Network, Toronto, Ontario, M5G 1X5, Canada.
Filiam YonathanDepartment of Microbiology, Mount Sinai Hospital/University Health Network, Toronto, Ontario, M5G 1X5, Canada.
Lucy ZhangDepartment of Microbiology, Mount Sinai Hospital/University Health Network, Toronto, Ontario, M5G 1X5, Canada.
Amelia Ayson-FortunatoDepartment of Microbiology, Mount Sinai Hospital/University Health Network, Toronto, Ontario, M5G 1X5, Canada.
Analiza AquinoDepartment of Microbiology, Mount Sinai Hospital/University Health Network, Toronto, Ontario, M5G 1X5, Canada.
Paul KrzyzanowskiOntario Institute for Cancer Research, Toronto General Hospital, Toronto, Ontario, M5G 0A3, Canada.
Jared SimpsonOntario Institute for Cancer Research, Toronto General Hospital, Toronto, Ontario, M5G 0A3, Canada.
John BartlettOntario Institute for Cancer Research, Toronto General Hospital, Toronto, Ontario, M5G 0A3, Canada.
Ilinca LunguOntario Institute for Cancer Research, Toronto General Hospital, Toronto, Ontario, M5G 0A3, Canada.
Bradly G WoutersPrincess Margaret Cancer Centre and Campbell Family Institute for Cancer Research, University Health Network, Toronto, Ontario, M5G 2C4, Canada.ORCID 0000-0002-8187-592X
James M RiniDepartments of Molecular Genetics and Biochemistry, University of Toronto, MaRS Center, Toronto, Ontario, M5G 1M1, Canada.
Michael GekasDepartment of Microbiology, Mount Sinai Hospital/University Health Network, Toronto, Ontario, M5G 1X5, Canada.
Susan PoutanenDepartment of Microbiology, Mount Sinai Hospital/University Health Network, Toronto, Ontario, M5G 1X5, Canada.
Laurence PelletierLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5, Canada.ORCID 0000-0003-1171-4618
Tony MazzulliDepartment of Microbiology, Mount Sinai Hospital/University Health Network, Toronto, Ontario, M5G 1X5, Canada.
Jeffrey L WranaLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5, Canada. wrana@lunenfeld.ca.ORCID 0000-0003-0932-0644

Funding

Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada) Grant #177705
6 · The paper itself

Abstract

Highly mutable pathogens generate viral diversity that impacts virulence, transmissibility, treatment, and thwarts acquired immunity. We previously described C19-SPAR-Seq, a high-throughput, next-generation sequencing platform to detect SARS-CoV-2 that we here deployed to systematically profile variant dynamics of SARS-CoV-2 for over 3 years in a large, North American urban environment (Toronto, Canada). Sequencing of the ACE2 receptor binding motif and polybasic furin cleavage site of the Spike gene in over 70,000 patients revealed that population sweeps of canonical variants of concern (VOCs) occurred in repeating wavelets. Furthermore, we found that VOC mutant derivatives and putative quasispecies that targeted functionally important residues and were found in future VOCs arose frequently, but were always extinguished. Systematic screening of functionally relevant domains in pathogens could thus provide a powerful tool for monitoring spread and mutational trajectories, particularly those with zoonotic potential.

Indexed as

COVID-19MutationSARS-CoV-2Spike Glycoprotein, CoronavirusUrban PopulationAngiotensin-Converting Enzyme 2High-Throughput Nucleotide SequencingHumansMutagenesisACE2 protein, humanAngiotensin-Converting Enzyme 2Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID39738001
PMCPMC11685962

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.